{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:31:28Z","timestamp":1792704688744,"version":"4.5.0"},"reference-count":43,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2016,5]]},"abstract":"Summary<\/jats:title>\n \n Background<\/jats:title>\n \n Vedolizumab (VDZ) is a humanised monoclonal IgG1 antibody targeting \u03b1\n 4<\/jats:sub>\n \u03b2\n 7<\/jats:sub>\n integrin.\n <\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n \n To investigate the real\u2010world efficacy of vedolizumab for the treatment of Crohn's disease (\n CD<\/jats:styled-content>\n ) and ulcerative colitis (\n UC<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A consecutive cohort of 212 adult\n IBD<\/jats:styled-content>\n patients with active disease (\n HBI<\/jats:styled-content>\n >7\/partial Mayo >4) newly receiving\n VDZ<\/jats:styled-content>\n was prospectively recruited from 7 academic and 17 community centres. The primary endpoint was clinical remission (\n CRM<\/jats:styled-content>\n ) (\n CD HBI<\/jats:styled-content>\n \u22644,\n UC<\/jats:styled-content>\n pMayo \u22641) in week 14. Secondary endpoints included steroid\u2010free remission (\n SFCRM<\/jats:styled-content>\n ), clinical response (\n CRS<\/jats:styled-content>\n ) (\n HBI<\/jats:styled-content>\n \/pMayo score drop \u22653), vedolizumab impact on\n CRP<\/jats:styled-content>\n , calprotectin and haemoglobin.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Data of 97\n CD<\/jats:styled-content>\n (71.1% female,\n HBI<\/jats:styled-content>\n 11) and 115\n UC<\/jats:styled-content>\n (42.6% female, pMayo 6) patients were analysed. Only 5.2%\n CD<\/jats:styled-content>\n and 24.3%\n UC<\/jats:styled-content>\n were anti\u2010\n TNF<\/jats:styled-content>\n \u03b1 na\u00efve. Most had extensive mucosal involvement (Montreal L3 69.1%\/E3 53.9%). At week 14, 23.7% vs. 23.5% of\n CD<\/jats:styled-content>\n vs.\n UC<\/jats:styled-content>\n patients achieved\n CRM<\/jats:styled-content>\n , 19.6% vs. 19.1%\n SFCRM<\/jats:styled-content>\n and 60.8% vs. 57.4%\n CRS<\/jats:styled-content>\n , respectively (all based on\n NRI<\/jats:styled-content>\n ). Week 14\n CRM<\/jats:styled-content>\n in\n CD<\/jats:styled-content>\n was significantly associated with no history of extraintestinal manifestations (\n P<\/jats:italic>\n = 0.019), no prior adalimumab use (\n P<\/jats:italic>\n = 0.011), no hospitalisation in the past 12 months (\n P<\/jats:italic>\n = 0.015) and low\n HBI<\/jats:styled-content>\n score (\n P<\/jats:italic>\n = 0.02) and in\n UC<\/jats:styled-content>\n with active or previous smoking (\n P<\/jats:italic>\n = 0.044\/0.028) and no anti\u2010\n TNF<\/jats:styled-content>\n \u03b1 (\n P<\/jats:italic>\n = 0.023) use. Low\n HBI<\/jats:styled-content>\n (\n P<\/jats:italic>\n = 0.019) and no hospitalisation in the past 12 months (\n P<\/jats:italic>\n = 0.01) predict\n CD CRM<\/jats:styled-content>\n . The three most common\n AE<\/jats:styled-content>\n were joint pain, acne and nasopharyngitis.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Vedolizumab is effective in routine use.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/apt.13594","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T13:30:41Z","timestamp":1459603841000},"page":"1090-1102","source":"Crossref","is-referenced-by-count":168,"title":["Vedolizumab induction therapy for inflammatory bowel disease in clinical practice \u2013 a nationwide consecutive German cohort study"],"prefix":"10.1111","volume":"43","author":[{"given":"D. C.","family":"Baumgart","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology Charit\u00e9 Medical School Humboldt\u2010University of Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Drabik","sequence":"additional","affiliation":[{"name":"Biostatistics Consulting M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stallmach","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases) University Hospital Jena Jena Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department Internal Medicine I University Hospital Schleswig\u2010Holstein Campus Kiel University of Schleswig\u2010Holstein Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Vedolizumab Germany Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60026-9"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60150-0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147364"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.1.32"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-011-0104-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/331041a0"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.17.8254"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90305-A"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/363461a0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","article-title":"Expression and function of the MAdCAM\u20101 receptor, integrin alpha 4 beta 7, on human leukocytes","volume":"153","author":"Erle DJ","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/382366a0"},{"key":"e_1_2_7_13_1","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule\u20101 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin M","year":"1997","journal-title":"Am J Pathol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178682"},{"key":"e_1_2_7_15_1","first-page":"147","article-title":"Designing biologic selectivity for inflammatory bowel disease \u2013 role of vedolizumab","volume":"9","author":"Krupka N","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153973"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.02.004"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.01.001"},{"key":"e_1_2_7_24_1","unstructured":"Medical Dicitionary for Regulatory Activities (MedDRA)The MSSO \u2013 Maintenance and Support Services Organization Chantilly VA USA 2013."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.02.002"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12086"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000396"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21643"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408506102"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302853"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2015.70"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307127"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13215"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.326"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000561"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)32956-5"},{"key":"e_1_2_7_38_1","doi-asserted-by":"crossref","first-page":"S866","DOI":"10.1016\/S0016-5085(15)32937-1","article-title":"Vedolizumab in the treatment of IBD: the University of Chicago experience","volume":"148","author":"Christensen B","year":"2015","journal-title":"Gastroenterology"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)32955-3"},{"key":"e_1_2_7_40_1","first-page":"A16","article-title":"The French real\u2010life experience of vedolizumab efficacy and safety in Crohn's disease: a prospective, observational multicenter cohort study","volume":"3","author":"Amiot A","year":"2015","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_2_7_41_1","first-page":"A16","article-title":"The French real\u2010life experience of vedolizumab efficacy and safety in ulcerative colitis: a prospective, observational multicenter cohort study","volume":"3","author":"Amiot A","year":"2015","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.08.019"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60661-9"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.226548"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13594","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:02:48Z","timestamp":1695499368000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/apt.13594"],"URL":"https:\/\/doi.org\/10.1111\/apt.13594","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}